Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MediciNova acquires two blood clotting agents
MN-447 and MN-462 are anti-clotting agents that represent novel approaches to blood clot formation and are expected to treat a variety of thrombotic disorders. Both agents have demonstrated
MN-447 and MN-462 are anti-clotting agents that represent novel approaches to blood clot formation and are expected to treat a variety of thrombotic disorders. Both agents have demonstrated
The study showed that the stem cell could differentiate into a type II alveolar lung cell. This advance in adult stem cell research could someday lead to treatments
The research reports the uptake of GTI-2040 in distinct subcellular compartments of leukemic cells that exceeded plasma levels. The data was consistent with previous findings, showing that GTI-2040
CVS operates the largest retail pharmacy chain in the US, with approximately 6,200 stores across 43 states. Caremark is one of the largest pharmacy benefit managers in the
MK-2295 is one of several drug candidates Merck is developing as part of its exclusive worldwide alliance with Neurogen to develop oral medicines targeting the VR1 receptor. The
Ceplene is EpiCept’s lead oncology product candidate that administered in conjunction with low dose interleukin-2 will be indicated for use in the maintenance of first remission in patients
Panzem is particularly targeting patients with ovarian cancer who have a clear cell subtype. Approximately 10% of ovarian cancer patients have clear cell histology, which is the most
The deal has been authorized on the basis of certain conditions. Watson and Andrx have agreed to a consent order to address concerns about the takeover and to
The phase III study evaluated the combination of torcetrapib and Lipitor (atorvastatin). Torcetrapib is an important drug in Pfizer’s pipeline and is seen as a replacement for Lipitor
The alliance is focused on the discovery and clinical development of nicotinic alpha-7 receptor agonists for the treatment of neurological and psychiatric disorders. The decision was triggered by